Predictive molecular pathology in metastatic thyroid cancer: the role of RET fusions. Issue 2 (4th March 2022)

• Record Type: Journal Article
• Authors: Nacchio, Mariantonia; Pisapia, Pasquale; Pepe, Francesco; Russo, Gianluca; Vigliar, Elena; Porcelli, Tommaso; Luongo, Cristina; Iaccarino, Antonino; Pagni, Fabio; Salvatore, Domenico; Troncone, Giancarlo; Malapelle, Umberto; Bellevicine, Claudio
• Is Part Of: Expert review of endocrinology & metabolism. Volume 17:Issue 2(2022)
• Page Start: 167
• Page End: 178
• Publication Date: 2022-03-04
• Subjects: Thyroid cancer -- RET fusion -- molecular pathology -- selpercatinib -- pralsetinib; Endocrinology -- Periodicals; Metabolism -- Periodicals; 616.4
• DOI: 10.1080/17446651.2022.2060819
• Languages: English
• ISSNs: 1744-6651

Abstract

ABSTRACT: Background: Rearranged during transfection ( RET ) gene fusions are detected in 10–20% of thyroid cancer patients. Recently, RET fusion-positive metastatic thyroid cancers have attracted much attention owing to the FDA approval of two highly selective anti-RET tyrosine kinase inhibitors, namely, selpercatinib, and pralsetinib. Areas covered: This review summarizes the available evidence on the biological and predictive role of RET gene fusions in thyroid carcinoma patients and the latest screening assays currently used to detect these genomic alterations in histological and cytological specimens. Expert opinion: Management of advanced thyroid carcinoma has significantly evolved over the last decade thanks to the approval of three multikinase inhibitors, i.e. sorafenib, lenvatinib, cabozantinib, and of two selective RET-tyrosine inhibitors, i.e. selpercatinib and pralsetinib. In this setting, the detection of RET-fusions in advanced thyroid cancer specimens through the use of next-generation sequencing has become a commonly used strategy in clinical practice to select the best treatment options.